Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II - Results from the 8-Week Dose-Escalation PeriodThomas Doeven, Andreas Glenthøj, Jonathan R.A. de Wilde et al.|Blood|2024Cited by 2
Ex vivo activation of pyruvate kinase improves red blood cell metabolism and hydration in hereditary spherocytosisJonathan R.A. de Wilde, Richard van Wijk, Titine J.J. Ruiter et al.|Blood Red Cells & Iron|2025Cited by 1
Red blood cell properties in hereditary xerocytosis and their response to ex vivo pyruvate kinase activation: a preliminary studyJonathan R.A. de Wilde, Richard van Wijk, Titine J.J. Ruiter et al.|Blood Red Cells & Iron|2025Cited by 0